Accessibility Menu
Lyra Therapeutics logo

Lyra Therapeutics(OTC) LYRA

Current Price$0.52
Market Cap$922.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-93%
1 Month-24%
Lyra Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.522026-07-20
Lyra Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.33%USD 0.482026-07-13
1 month-23.53%USD 0.682026-06-18
3 month-30.9%USD 0.752026-04-21
Year to date-83.12%USD 3.082025-12-31
1 year-93.42%USD 7.902025-07-18
3 year-99.69%USD 166.002023-07-21
5 year-99.86%USD 374.502021-07-21
Since inception-99.94%USD 928.002020-05-01

Lyra Therapeutics Financials at a Glance

Market Cap

$922.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$398.00K

Net Income (TTM)

-$28.92M

EPS (TTM)

-$19.31

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.03 (Low)

Price

$0.52

Volume

12

Open

$0.45

Previous Close

$0.52

Daily Range

$0.36 - $0.52

52-Week Range

$0.30 - $8.75

Estimated Earnings Date

May 12, 2026

LYRA News

Foolcom-Featured.png

Lyra Therapeutics Posts 85% Q2 Loss Drop

Motley Fool Markets TeamAug 12, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lyra Therapeutics

Lyra develops treatments for people with chronic sinus inflammation. Its main products deliver medicine directly to affected nasal tissue. These therapies aim to reduce symptoms for patients who do not respond to standard treatments.

Products and Services

  • LYR-210 (Implantable Drug Matrix): Delivers anti-inflammatory medicine for six months to treat chronic rhinosinusitis (CRS); 0% of revenue in 2025 as no product sales occurred.
  • LYR-220 (Expanded Use Device): Designed for CRS patients with larger nasal cavities or prior sinus surgery; development paused in 2024; 0% of revenue in 2025.
  • Collaboration Revenue: All 2025 revenue came from licensing agreements, mainly with LianBio, not from product sales (100% of revenue).
  • Drug Delivery Platform: Uses a bioabsorbable mesh to release medicine locally over time, targeting hard-to-reach sinus tissue.

Growth and Expansion

  • Signed a collaboration with LianBio in 2021 to develop LYR-210 in China and Southeast Asia.
  • Paused all research and development activities for LYR-210 and LYR-220 in January 2026 after clinical trial setbacks.
  • Raised $5 million in June 2025 through a direct offering and private placement.
  • Reduced workforce by 75% in mid-2024 and further in early 2026 to cut costs.
  • Currently evaluating strategic alternatives, including mergers, asset sales, or liquidation.

What Makes Lyra Stand Out

Lyra’s technology delivers drugs directly to inflamed sinus tissue, aiming for longer-lasting relief. Its intellectual property portfolio covers drug delivery methods through 2042. The company’s focus on local, sustained therapy addresses gaps in current sinus disease treatments.

Five Things You Need to Know

  • 2025 revenue was $25,000, down 87.2% from 2024.
  • All revenue in 2025 came from licensing, not product sales.
  • Net loss improved to $(28.9) million in 2025 from $(93.4) million in 2024.
  • Cash and equivalents fell to $15.9 million at end of 2025.
  • Delisted from Nasdaq in March 2026 due to lack of operating business.

Bottom Line

Lyra shifted from drug development to cost-cutting after clinical trial failures. The company now seeks strategic options amid ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

27

CEO

Maria Palasis, PhD

Website

www.lyratherapeutics.com

Headquarters

Watertown, MA 02472, US

LYRA Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-7794.47%

Net Income Margin

-7266.08%

Return on Equity

1211.14%

Return on Capital

-158.75%

Return on Assets

-80.09%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$922.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.77M

Volume

12

Avg. Volume

12.82K

Financials (TTM)

Gross Profit

$398.00K

Operating Income

-$31.02M

EBITDA

-$27.76M

Operating Cash Flow

-$28.86M

Capital Expenditure

-$116.00K

Free Cash Flow

-$28.98M

Cash & ST Invst.

$15.89M

Total Debt

$30.26M

Lyra Therapeutics Performance Analysis

Lyra Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,363,000378.2%
20232023-12-31USD 1,558,00014.3%
20242024-12-31USD 1,534,000-1.5%
20252025-12-31USD 398,000-74.1%
Lyra Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-12.4%
Q22025-06-30N/A
Q32025-09-30-86.3%
Q42025-12-31-72.0%
Lyra Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -91.41-45.4%
20232023-12-31USD -62.93-31.2%
20242024-12-31USD -71.7514.0%
20252025-12-31USD -18.62-74.1%
Lyra Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3123.5%
Q22025-06-30-4138.5%
Q32025-09-3038.7%
Q42025-12-31-184.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$7.00K

-96.7%

Gross Profit

$307.00K

+46.9%

Gross Margin

43.86%

N/A

Market Cap

$922.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$30.76K

N/A

Employees

30

N/A

Net Income

-$6.95M

+36.7%

EBITDA

-$6.81M

+29.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$15.89M

-60.8%

Total Debt

$30.26M

-12.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$25.44M

-15.9%

Short Term Debt

$4.82M

+16.9%

Return on Assets

-80.09%

N/A

Return on Invested Capital

-1.17%

N/A

Free Cash Flow

-$6.16M

+45.4%

Operating Cash Flow

-$6.07M

+46.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HCWBHCW Biologics Inc.
$3.94+2.87%
CDIOCardio Diagnostics Holdings, Inc.
$1.68+3.07%
RNAZTransCode Therapeutics, Inc.
$8.42-3.55%
BOLTBolt Biotherapeutics, Inc.
$4.30-3.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$6.71+2.88%
NOKNokia
$10.71+0.06%
UTZUtz Brands
$14.11+0.89%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.41+0.06%

Questions About LYRA

What is the current price of Lyra Therapeutics?

Lyra Therapeutics is trading at $0.52 per share.

What is the 52-week range for Lyra Therapeutics?

Over the past 52 weeks, Lyra Therapeutics has traded between $0.30 and $8.75.

How much debt does Lyra Therapeutics have?

As of the most recent reporting period, Lyra Therapeutics reported total debt of $30.26M.

How much cash does Lyra Therapeutics have on hand?

Lyra Therapeutics reported $15.89M in cash and cash equivalents in its most recent financial results.

What is Lyra Therapeutics’s dividend yield?

Lyra Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services